Rosanova María T, Sarkis Claudia, Escarra Florencia, Epelbaum Carolina, Sberna Norma, Carnovale Susana, Figueroa Carlos, Bologna Rosa, Lede Roberto
Servicio de Infectología, Hospital de Pediatría "Prof. Dr. J. P. Garrahan", Ciudad Autónoma de Buenos Aires, Argentina.
Servicio de Farmacia, Hospital de Pediatría "Prof. Dr. J. P. Garrahan", Ciudad Autónoma de Buenos Aires, Argentina.
Arch Argent Pediatr. 2017 Aug 1;115(4):374-376. doi: 10.5546/aap.2017.eng.374.
The experience using anidulafungin for the treatment of invasive fungal infections in pediatrics is limited. In this article, we describe our experience in 55 children. Anidulafungin was administered intravenously at a loading dose of 3 mg/kg once daily, followed by 1.5 mg/kg every 24 hours over a mean period of 14 days (range: 7-22 days). Patients' median age was 114 months old (interquartile range: 32-168 months old). All patients had underlying diseases. Among patients with bone marrow transplant, the difference in white blood cell count, transaminase levels, and renal function at baseline and at the end of anidulafungin administration was not significant. No adverse events were reported and no patient died from an anidulafungin-related cause. Anidulafungin may be considered an alternative for the prophylaxis or treatment of invasive fungal infections in pediatrics but methodologically robust studies are needed to confirm this.
在儿科中使用阿尼芬净治疗侵袭性真菌感染的经验有限。在本文中，我们描述了我们对55名儿童的治疗经验。阿尼芬净静脉给药，负荷剂量为3mg/kg，每日1次，随后每24小时给予1.5mg/kg，平均疗程为14天（范围：7 - 22天）。患者的中位年龄为114个月（四分位间距：32 - 168个月）。所有患者均有基础疾病。在骨髓移植患者中，阿尼芬净给药基线和结束时白细胞计数、转氨酶水平及肾功能的差异无统计学意义。未报告不良事件，也没有患者死于与阿尼芬净相关的原因。阿尼芬净可被视为儿科侵袭性真菌感染预防或治疗的一种替代药物，但需要方法学严谨的研究来证实这一点。
